WO1993014773A1 - Composition pharmaceutique et son utilisation - Google Patents

Composition pharmaceutique et son utilisation Download PDF

Info

Publication number
WO1993014773A1
WO1993014773A1 PCT/SE1993/000033 SE9300033W WO9314773A1 WO 1993014773 A1 WO1993014773 A1 WO 1993014773A1 SE 9300033 W SE9300033 W SE 9300033W WO 9314773 A1 WO9314773 A1 WO 9314773A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
several
vitamin
disaccharides
cream
Prior art date
Application number
PCT/SE1993/000033
Other languages
English (en)
Inventor
Rune SÖREMARK
Original Assignee
Soeremark Rune
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soeremark Rune filed Critical Soeremark Rune
Publication of WO1993014773A1 publication Critical patent/WO1993014773A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Definitions

  • the present invention relates to a pharmaceutical composi ⁇ tion, e.g. an ointment, a cream or a paste, which can be used to treat superficial skin and mucous membrane affec ⁇ tions.
  • a pharmaceutical composi ⁇ tion e.g. an ointment, a cream or a paste
  • the invention also relates to the use of this compo- sition to produce a pharmaceutical preparation designed to treat such superficial affections. This preparation may be used to treat human beings as well as animals.
  • a su ⁇ gar ointment is used successfully against acute mediasti- nitis subsequent to heart surgery operations, against se ⁇ vere burns etc.
  • disaccharides such as sacc- harose, meltose and cellobiose, all of which have the mole ⁇ cular formula C- 2 H Trust 2 0,.
  • monosaccharides such as hexoses, e.g. glucose, fructose or galactose, all of which have the structural formula C6H-1.206 r and certain glycosides are active.
  • vitamin E is an excellent antioxidant and is able to contribute to the stability of the cell memb ⁇ ranes by protecting the polyunsaturated fatty acids in the lipids of the membrane against attacks by free radicals.
  • a pharmaceutical composition which consists of a mixture, which comprises zinc oxide (ZnO) , one or several of the substances, which belong to any ofthe groups disaccharides, monosaccharides and glycosides as well as vitamin E in effective amounts in a pharmaceutically and cosmetically acceptable vehicle, which gives the mix ⁇ ture the consistency of an ointment, cream or paste,
  • the mixture can and ought to include at least one or seve- ral of the substances zinc sulphate (ZnSO.) , vitamin A and boric acid (H.,BO-,) .
  • Zinc oxide has in in vitro-examinations proved to have a satisfactory antimicrobial and antidermatophytic effect. It is also astringent and locally protective, antiphlogistic and antipruritic and ought to be included in the composi ⁇ tion in a minimum amount of 5 percent by weight, preferab ⁇ ly at least 15 percent by weight and suitably at least 20 percent by weight in order to obtain the desired effect.
  • the maximum amount depends on the consistency requirements and is not more than 60 %, preferably not more than 50 %, suitably not more than 45 %.
  • An optimal amount is about 30 or not more than 35 percent by weight.
  • composition according to the invention is to include some type of sugar.
  • Saccharose which is a disaccharide with the molecular formula c ⁇ 2 H 22 ° 11 ' anc P art i cular ly glucose, which is a monosaccharide (hexose) with the structural for- ula C g H., 2 Og have proven to be active.
  • certain glyco ⁇ sides can be considered as alternatives or supplements to disaccharides and/or monosaccharides.
  • composition of the present invention one or several of the substances, which belong to any of the groups disaccharides, monosaccha ⁇ rides and glycosides, are to be included in it in an amount of 10-70 percent by weight, preferably 10-50 percent by weight and suitably 15-45 %.
  • An optimal amount is 15-35 .
  • Vitamin E is an excellent antioxidant and contributes to the stability of the cell membranes by protecting the poly- unsaturated fatty acids in the lipids of the membrane from attacks by free radicals and oxidation. Vitamin E appears in the composition according to the invention, due to its protective action, to provide a synergistic effect in com ⁇ bination with zinc oxide and the above-mentioned type(s) of sugar. Consequently, vitamin E ought to be included in a minimum amount of 5 percent by weight and suitably at least 10 percent by weight in order to obtain said effects to the desired extent. The maximum amount may be as high as 30 % and suitably not more than 20 %. An optimal amount is about 15 percent by weight.
  • a preferred vehicle is the so called Essex cream, which is a trade name for a fatty cream, which in addition to the main components vaseline and liquid paraffin includes emulsifiers as well as preservatives and pH value-adj stment agents.
  • Other suitable vehicles are e.g. pure vaseline, Lo- cobase and cod liver oil (the latter mainly for veterinary use) .
  • the above-mentioned ingredients are unconditional substances in the composition according to the invention.
  • the condi ⁇ tional substances which preferably are to be included in the composition, can be added in the following concentra ⁇ tions: Zinc sulphate, which is astringent and antiphlogistic, can and ought to - dissolved in a small amount of water - al ⁇ so be used in a minimum amount of 0.5 %, not more than 3 %.
  • An optimal amount is about 1 percent by weight.
  • Vitamin A is important for the growth and the function of epithelial tissues of the skin and ought to be included in the composition in a minimum amount of 0.01 and mot more than 3 percent by weight, preferably not more than 1 per ⁇ cent by weight, suitably not more than 0.5 percent byweight.
  • a suitable amount is about 0.2 percent by weight.
  • Boric acid which denatures proteins, is astringent and an ⁇ tiseptic, bacteriostatic and fungistatic, can be added in a minimum amount of 0.5 %.
  • boron compounds may have certain adverse effects, e.g. having an irritating effect on mucous membranes, and consequently, boric acid should not be added in a larger amount than 3 percent by weight.
  • An optimal amount is about 1 percent by weight.
  • an ointment which for each 100 g comprises 32 g ZnO, 1 g ZnSO. inwater solution, 25 g glucose, 1 g H.,B0 3 , 15 g vitamin E (tokoferoliacetas (al- fa) 20.400 IE), 0.2 g vitamin A (retinolipalmitas 0.34 mil IE) and the rest a pharmaceutically and cosmetically accep ⁇ table vehicle, more particularly an Essex ointment, which includes about 0.5 % chlorocresol as a preservative.
  • the cream according to the invention was added to the DST- medium, with and without additives, concentrations of 40,
  • Control plates were made with distilled wa- ter. Plates were inoculated with 10 cells/ml (0.1 ml) of P. ovale. The rest of the microorganisms were inoculated in a concentration of 10 cells/ml (0.1 ml). P. ovale was read after an incubation of 3 days. Pr. acnes was incubated anae- robicly and was read after 2 days. The rest of the bacteria and C. albicans were read after an incubation time of 1 day. The plates incubated at 37 C.
  • the least inhibitory concentration (MIC) was registered for the minimum concent ⁇ ration of the cream according to the invention, at which a total growth inhibition could be registered.
  • Table 1 shows the MIC-values for various microorganisms. St. haemolytica was the most susceptible organism with a MIC-value of 0.5 %, whereas C. albicans was the most resis ⁇ tant with a MIC-value of 10 %.
  • the study shows that the cream according to the invention is active in vitro against a plurality of microorganisms , which are found in many skin affections, e.g. those mentioned above and impetigo, acne vulgaris as well as Pityrosporum-related problems, including seborrhoeic dermatitis, pityriasis versicolor and cutaneous candidiasis.
  • MIC minimum inhibitory concentration of the preparation according to the inven ⁇ tion
  • the cream according to the invention as a local treatment- agent for a mild form av acne vulgaris was evaluated.
  • the study was performed at the skin department of a large Swe- dish hospital. Patients having a mild form of acne were se ⁇ lected. After a washout-period of two weeks the treatment with the cream was started, the cream having the same com ⁇ position as in the in vitro-examination, in the morning and in the evening in an open procedure. The patients were eva- luated on day 0, day 7, days 14-21 as well as days 35-42 at the skin department. The number of papules and pustules in the face was counted at every visit.
  • the cream had the same composition as the cream used to te acne and was applied by the animal owner 1 or 2 times a da after a cleaning of the sore.
  • a control of the results was carried out after a week and in some cases after two weeks in the animal hospital. Due to. a substantial travel dis ⁇ tance to the hospital the results in a few cases were re ⁇ ported by the animal owner on the telephone.
  • the evaluatio of the results was .made on a scale of 1-4 and by one and t same person according the following: 4 Very excellent The result visible after one day.
  • the lesion is healed within 2 weeks Satisfactory The result is obvious, but it takes more than 2 weeks for the lesion to heal.
  • Diagnosis Number Evaluation 4 3 2 skin-fold dermatitis 11 9 1 1 blisters 6 6 scurs hosp/cracked pads 3 3 sores slow in healing 24 10 5 0 other skin lesions 16 2 1 4
  • the cream according to the invention has an excellent healing effect on skin sores on dogs.
  • the preparation also has an excellent adherence to the skinand the sore.
  • the cream has after a cleaning of the sore been applied and new plaster cast has then been app ⁇ lied.
  • the sores have been healed.
  • Excellent results have also been obtained for large skin sores. They will heal quickly after the cream has been applied.
  • the cream was also tested on 7 dogs, operated on for anal fistula. The cream was applied on the open sore. Since the sores were large, it took in some cases more than 14 days to heal. However, in all those 7 cases a considerably better and quicker healing could be observed with the cream than without.
  • the cream showed less excellent results on scurs hosp, cracked pads and excema on paws. Tests on horses
  • the cream was applied by a veterinary or a horse owner.
  • the applications were done after a cleaning of the sore 1-2 times every day.
  • a light-weight dressing has been applied on top of the cream.
  • no sore dres ⁇ sing has been used, only the cream.
  • the number of applica ⁇ tions for every treatment i.e. up to a healing or up to the moment when the treatment has been discontinued (name- ly in those 8 instances when no healing could be observed) , has varied between 4-13 applications.
  • Tested skin lesions as well as the bases for forming the evaluations of the healing result are shown in Table 4.
  • the compilation is based on the data, which have been re ⁇ ported by the veterinaries.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition pharmaceutique, par exemple une pommade, une crème ou une pâte, utilisable pour traiter les affections superficielles de la peau ou des muqueuses. La composition est constituée d'un mélange de 5 à 60 % en poids de ZnO; de 10 à 70 % en poids d'une ou plusieurs substances comprises dans un ou plusieurs groupes parmi les disaccharides, les monosaccharides et les glycosides; et de 3 à 30 % en poids de vitamine E; le solde n'étant principalement constitué que d'excipients pharmaceutiquement acceptables.
PCT/SE1993/000033 1992-01-24 1993-01-21 Composition pharmaceutique et son utilisation WO1993014773A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9200199A SE9200199L (sv) 1992-01-24 1992-01-24 Farmaceutisk komposition och dess anvaendning
SE9200199-9 1992-01-24

Publications (1)

Publication Number Publication Date
WO1993014773A1 true WO1993014773A1 (fr) 1993-08-05

Family

ID=20385108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1993/000033 WO1993014773A1 (fr) 1992-01-24 1993-01-21 Composition pharmaceutique et son utilisation

Country Status (3)

Country Link
AU (1) AU3465393A (fr)
SE (1) SE9200199L (fr)
WO (1) WO1993014773A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710526A1 (fr) * 1993-09-29 1995-04-07 Phil International Inc Préparation cosmétique à l'oxyde de zinc et son procédé de fabrication.
FR2717079A1 (fr) * 1994-03-11 1995-09-15 Oreal Composition contenant un oxyde de métal non photocatalytique et du tocophérol, son utilisation dans le domaine cosmétique et/ou dermatologique et procédés la mettant en Óoeuvre.
WO1996023479A2 (fr) * 1995-02-03 1996-08-08 Beiersdorf Ag Principes actifs anti-adherents
WO2000032155A2 (fr) * 1998-12-04 2000-06-08 Johnson And Johnson Consumer Companies, Inc. Compositions pour soins de la peau renfermant des sels de zinc et des retinoides
EP1072268A1 (fr) * 1997-11-24 2001-01-31 Zhongming Zeng Formulation pharmaceutique de stimulation de la croissance de bacilles gram positif et d'augmentation de l'acidite du vagin et son utilisation
WO2003092703A1 (fr) * 2002-04-30 2003-11-13 Hisamitsu Pharmaceutical Co., Inc. Procedes et compositions pour inhiber l'irritation au moyen d'un disaccharide et d'ions metalliques
EP1593381A1 (fr) * 2003-11-26 2005-11-09 Tecnologia & Vitaminas, S.L. Compositions a base d'oxyde de zinc pur le traitement et la prevention de la diarrhee chez l'animal
US6964949B2 (en) 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
FR2883750A1 (fr) * 2005-04-04 2006-10-06 Virbac Sa Sa Compositions topiques et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002845A1 (fr) * 1983-01-21 1984-08-02 Advanced Drug Tech Onguent pour les soins de la peau contenant des vitamines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002845A1 (fr) * 1983-01-21 1984-08-02 Advanced Drug Tech Onguent pour les soins de la peau contenant des vitamines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Volume 23, No. 5, May 1983, JORGE CHIRIFE et al., "In Vitro Study of Bacterial Growth Inhibition in Concentrated Sugar Solutions: Microbiological Basis for the Use of Suger in Treating Infected Wounds", page 766 - page 773. *
CHEMICAL ABSTRACTS, Volume 113, No. 10, 3 Sept 1990, (Columbus, Ohio, USA), United States Food and Drug Adm., "Skin Protectant Drug Products for Over-the-Counter Human Use; Proposed Rulemaking for Diaper Rash Drug Products", page 404, Abstract No. 84672h; & FED. REGIST., 1990, 55(119), 25204-25232. *
JORGE CHIRIFE et al., "Scientific Basis for Use of Granulated Sugar in Treatment of Infected Wounds", 1982, THE LANCET, page 560 - page 561. *
JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND, Volume 69, No. 7, 1986, KASIAN BHANGANADA et al., "The Use of Super - Saturated Sucrose Solution for Chronic Skin Ulcers", page 358 - page 366. *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710526A1 (fr) * 1993-09-29 1995-04-07 Phil International Inc Préparation cosmétique à l'oxyde de zinc et son procédé de fabrication.
US6103247A (en) * 1994-03-11 2000-08-15 L'oreal Composition containing a non-photocatalytic metal oxide and tocopherol, its use in the cosmetics and/or dermatological field and processes employing it
FR2717079A1 (fr) * 1994-03-11 1995-09-15 Oreal Composition contenant un oxyde de métal non photocatalytique et du tocophérol, son utilisation dans le domaine cosmétique et/ou dermatologique et procédés la mettant en Óoeuvre.
EP0676187A2 (fr) * 1994-03-11 1995-10-11 L'oreal Composition contenant un oxyde de métal non photocatalytique et du tocophérol, son utilisation dans le domaine cosmétique et/ou dermatologique et procédés la mettant en oeuvre
US5695771A (en) * 1994-03-11 1997-12-09 L'oreal Composition containing a non-photocatalytic metal oxide and tocopherol its use in treating light induced signs of aging
EP0676187A3 (fr) * 1994-03-11 1997-12-29 L'oreal Composition contenant un oxyde de métal non photocatalytique et du tocophérol, son utilisation dans le domaine cosmétique et/ou dermatologique et procédés la mettant en oeuvre
WO1996023479A2 (fr) * 1995-02-03 1996-08-08 Beiersdorf Ag Principes actifs anti-adherents
WO1996023479A3 (fr) * 1995-02-03 1997-03-06 Beiersdorf Ag Principes actifs anti-adherents
EP1072268A1 (fr) * 1997-11-24 2001-01-31 Zhongming Zeng Formulation pharmaceutique de stimulation de la croissance de bacilles gram positif et d'augmentation de l'acidite du vagin et son utilisation
EP1072269A1 (fr) * 1997-11-24 2001-01-31 Zhongming Zeng Formulation pharmaceutique de stimulation de la croissance de bacilles gram positifs et d'augmentation de l'acidite du vagin et leur utilisation
EP1072269A4 (fr) * 1997-11-24 2003-08-27 Zhongming Zeng Formulation pharmaceutique de stimulation de la croissance de bacilles gram positifs et d'augmentation de l'acidite du vagin et leur utilisation
EP1072268A4 (fr) * 1997-11-24 2003-09-03 Zhongming Zeng Formulation pharmaceutique de stimulation de la croissance de bacilles gram positif et d'augmentation de l'acidite du vagin et son utilisation
WO2000032155A2 (fr) * 1998-12-04 2000-06-08 Johnson And Johnson Consumer Companies, Inc. Compositions pour soins de la peau renfermant des sels de zinc et des retinoides
WO2000032155A3 (fr) * 1998-12-04 2000-11-23 Johnson & Johnson Consumer Compositions pour soins de la peau renfermant des sels de zinc et des retinoides
US6964949B2 (en) 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
WO2003092703A1 (fr) * 2002-04-30 2003-11-13 Hisamitsu Pharmaceutical Co., Inc. Procedes et compositions pour inhiber l'irritation au moyen d'un disaccharide et d'ions metalliques
EP1593381A1 (fr) * 2003-11-26 2005-11-09 Tecnologia & Vitaminas, S.L. Compositions a base d'oxyde de zinc pur le traitement et la prevention de la diarrhee chez l'animal
ES2344442A1 (es) * 2003-11-26 2010-08-26 TECNOLOGIA & VITAMINAS, S.L., Adicion a la patente de invencion 200302779 por "formulacion a base de oxido de cinc para la prevencion y el tratamiento de diarrea en animales de granja".
FR2883750A1 (fr) * 2005-04-04 2006-10-06 Virbac Sa Sa Compositions topiques et leurs utilisations
WO2006106220A2 (fr) * 2005-04-04 2006-10-12 Virbac Sa Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage
WO2006106220A3 (fr) * 2005-04-04 2007-01-04 Virbac Sa Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage
JP2008534659A (ja) * 2005-04-04 2008-08-28 ヴィルバック・ソシエテ・アノニム 局所用組成物およびその使用
AU2006231248B2 (en) * 2005-04-04 2012-08-02 Virbac Sa Topical compositions comprising several mono- and/or oligosaccharides for treating skin diseases of warm blood hair coated animals.

Also Published As

Publication number Publication date
SE9200199D0 (sv) 1992-01-24
SE9200199L (sv) 1993-07-25
AU3465393A (en) 1993-09-01

Similar Documents

Publication Publication Date Title
DE60032543T2 (de) Topisch verabreichbare Zinkzusammensetzungen
CA1050548A (fr) Sulfadiazine zinc utilise comme medicament
KR950702834A (ko) 글루칸 제제(novel glucan preparation)
EP0103878B1 (fr) Préparations pour le traitement des plaies de la surface de la peau et procédé pour leur obtention
JP2005505543A (ja) エミュー基剤の創傷治療用製剤
BG64522B1 (bg) Средство за лечение на вирусни инфекциозни заболявания
CN87104644A (zh) 广谱杀病毒剂
GB2057875A (en) Dimethyl sulphoxide compositions
DE60112431T2 (de) Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
WO1993014773A1 (fr) Composition pharmaceutique et son utilisation
RU2470640C1 (ru) Средство для лечения воспалительных заболеваний полости рта и способ лечения воспалительных заболеваний полости рта
US6022862A (en) Use of pseudopterosins for promoting wound healing
NL9220019A (nl) Farmaceutische samenstelling.
US4444751A (en) Neutralizing composition for sting venoms
DE69333258T2 (de) Verwendung von lysozymdimer zur herstellung eines arzneimittels zur modulation der natürlichen abwehrvorgänge
RU2417102C2 (ru) Фармацевтическая гелесодержащая композиция для местного и наружного применения
RU2412719C2 (ru) Средство против экземы "проксилан"
WO2022075888A1 (fr) Composition aqueuse bactéricide pour traiter des maladies infectieuses des sabots
KR20230010202A (ko) 미생물 감염의 치료를 위한 프로테아제 제형
US3026247A (en) Pharmaceutical preparation
DE202011111037U1 (de) Vorrichtung zur Behandlung von Zahnfleischerkrankung
RU2771010C1 (ru) Препарат для лечения кошек при дерматитах различной этиологии
RU2745236C1 (ru) Способ лечения и профилактики субклинического мастита у коров
RU2788332C1 (ru) Мазь для лечения травматического повреждения кожных покровов
CA2254878A1 (fr) Medicament topique comprenant un biocide phenolique et de la choline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Ref country code: BY

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: BY

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA